Targeted Therapies in Early Stage NSCLC: Hype or Hope?

Alex Friedlaender 1,†, Alfredo Addeo 1,†, Alessandro Russo 2, Vanessa Gregorc 3, Diego Cortinovis 4 and Christian D. Rolfo 5,*

1 Oncology Department, University Hospital of Geneva, 1205 Genève, Switzerland; alex.friedlaender@hcuge.ch (A.F.); alfredo.addeo@hcuge.ch (A.A.)
2 Medical Oncology Unit, A.O. Papardo, 98158 Messina, Italy; ale.russo1986@gmail.com
3 Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, 20132 Milan, Italy; vanesa.gregorc@hsr.it
4 SC Medical Oncology, Azienda Socio Sanitaria Territoriale (ASST) H S Gerardo Monza, 20900 Monza, Italy; d.cortinovis@asst-monza.it
5 Thoracic Oncology Department and Early Phase Clinical Trials Section, School of Medicine, University of Maryland, Baltimore, MD 20742, USA
* Correspondence: christian.rolfo@umm.edu; Tel.: +410-328-7904; Fax: +410-328-9160
† They are co-first authors.

Received: 14 August 2020; Accepted: 26 August 2020; Published: 31 August 2020

Abstract: Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that increases yearly across the world. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in survival and quality of life in locally advanced and metastatic NSCLC. In particular, oncogenic drivers have indeed transformed the therapeutic algorithm for NSCLC. Nearly 25% of patients are diagnosed in an early stage when NSCLC is still amenable to radical surgery. In spite of this, five-year survival rates for fully resected early stage remains rather disappointing. Adjuvant chemotherapy has shown a modest survival benefit depending on the stage, but more than half of patients relapse. Given this need for improvement, over the last years different targeted therapies have been evaluated in early-stage NSCLC with no survival benefit in unselected patients. However, the identification of reliable predictive biomarkers to these agents in the metastatic setting, the design of molecularly-oriented studies, and the availability of novel potent and less toxic agents opened the way for a novel era in early stage NSCLC treatment. In this review, we will discuss the current landscape of targeted therapeutic options in early NSCLC.

Keywords: NSCLC; targeted therapy; early stage; EGFR; ALK; osimertinib

1. Introduction

Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that keeps rising across the globe [1]. The treatment landscape of metastatic NSCLC has considerably improved over the last two decades due to a better understanding of cancer biology [2]. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in overall survival (OS) and quality of life (QoL) in advanced/metastatic disease [3].

Oncogenic drivers have indeed reshaped the therapeutic algorithm for metastatic NSCLC, making us wonder whether they could also play a role in early disease. Roughly a quarter of patients are diagnosed with disease amenable to potentially radical surgery [3].

In spite of this, five-year survival rates for fully resected stage I disease range from 50 to 70% while lying between 10 and 30% for stage IIIA NSCLC [4].
Adjuvant chemotherapy has shown a modest survival benefit (with an absolute increase in survival of 4% at five years), but, depending on the stage [5,6], more than half of patients still relapse [7]. Similarly, a neoadjuvant approach yields a 5% absolute benefit on five-year survival [8], leaving room for improvement. The question of whether targeted therapy could fill this unmet medical need is far from new. Over the last several years, different targeted therapies have been evaluated in early stage NSCLC with no survival benefit in unselected patients [9–12]. However, the identification of reliable predictive biomarkers to these agents in the metastatic setting, the design of molecularly-oriented studies, and the availability of novel potent and less toxic agents paved the way for a novel era in early stage NSCLC treatment (Figure 1). In this review, we will discuss the current landscape of targeted therapeutic options being investigated in early NSCLC.

Figure 1. Potential role of targeted therapies in the adjuvant setting. Post-operative platinum-based chemotherapy (CHT) in stage IB-IIIA resected non-small-cell lung cancer (NSCLC) has been associated with a 4% survival benefit at 5 years [7]. According to the Lung Adjuvant Cisplatin Evaluation (LACE) study, 5-year recurrence rates range from 45% in stage IB to 76% in stage III after adjuvant chemotherapy [8]. Post-operative radiotherapy (PORT) is currently recommended in patients with pathologic N2 (pN2) disease and in those with microscopic (R1) or macroscopic (R2) residual disease.

2. Epidermal Growth Factor Receptor (EGFR) mutations

In EGFR mutant NSCLC, the most common oncogenic driver targeted today, the question of adding a tyrosine kinase inhibitor (TKI) or replacing chemotherapy with one is not new. Before EGFR mutations were identified as the major determinants of efficacy to first-generation EGFR TKIs in 2004 [13,14], two randomized phase III trials assessed the impact of erlotinib (RADIANT) [9] and gefitinib (BR19) [10] in unselected stage IB-IIIA NSCLCs. The RADIANT trial enrolled patients with fully resected stage IB to IIIA NSCLC and confirmed tumor EGFR expression by immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). Patients were randomized in a 2:1 ratio to receive daily erlotinib for two years or placebo. When indicated, patients received adjuvant chemotherapy before starting the study therapy. The primary endpoint of improved DFS was not met. It is noteworthy that only 163 out of 973 patients recruited in the study harbored an exon 19 deletion or L858R EGFR
mutation. In this specific subgroup of EGFR-driven diseases, DFS was superior with erlotinib (HR, 0.61; 95% CI, 0.384–0.981; \( p = 0.0391 \)). This difference could not be retained as statistically significant, given the hierarchical testing that allowed assessment of secondary endpoints only if the primary endpoint was statistically significant. The follow-up was too short at the time of the analysis to properly assess survival differences. The phase 3 BR19 study assessed the role of gefitinib as adjuvant therapy for up to two years versus placebo in patients with completed resected stage IB to IIIA NSCLC. At a median follow-up of 4.7 years among 503 patients, there was neither DFS (1.22, 95% CI 0.90–1.71) nor OS (HR 1.24, 95% CI 0.94–1.64) benefit in the experimental arm. The trial was closed early. No benefit was also observed in the small subgroup of patients harboring EGFR mutations in terms of both DFS (HR, 1.84; 95% CI, 0.44 to 7.73; \( p = 0.395 \)) and OS (HR, 3.16; 95% CI, 0.61 to 16.45; \( p = 0.15 \)) [10].

Following the successful experience in advanced/metastatic setting with multiple EGFR TKIs approved in molecularly selected patients [15–19] different studies have sought to demonstrate a survival advantage with the use of these agents as adjuvant therapy in EGFR-mutated radically resected NSCLCs (Table 1). Nevertheless the role of co-mutations remains unclear [20].

The SELECT trial is a single-arm phase 2 trial and was the first to test the efficacy of adjuvant erlotinib in resected EGFR-mutated NSCLC. One hundred patients with stage IA to IIIA EGFR mutant NSCLC were given erlotinib for up to two years after completing standard adjuvant therapy. The 2-year DFS was 88%, and the authors concluded that this was an improvement compared to historical matched controls, which had a two-year DFS of 76%. Furthermore, the median time to recurrence was 25 months after discontinuing erlotinib [11]. Since then, a number of randomized adjuvant targeted therapy trials have been published.

The CTONG1104/ADJUVANT trial is a phase 3 study that compared the standard cisplatin-vinorelbine chemotherapy to gefitinib, a first-generation EGFR TKI in fully resected stage II to IIIA EGFR mutant NSCLC [12]. Chemotherapy was administered for four cycles, while gefitinib was given until progression for up to two years. The primary endpoint was disease-free survival (DFS), while OS was a secondary endpoint. At a median follow-up of 36.5 months, the experimental arm yielded a superior DFS compared to chemotherapy (28.7 versus 18.0 months), with a hazard ratio (HR) of 0.60 (95% CI 0.42–0.87, \( p = 0.0054 \)). The mature OS results were presented at the American Society of Clinical Oncology (ASCO) 2020 Meeting, with a median follow-up of 76.9 months. The median OS was not statistically different, at 75.5 months in the gefitinib arm and 79.2 months in the chemotherapy arm (HR 0.92, 95% CI 0.62–1.36). Furthermore, only 51.5% of patients in the chemotherapy arm were exposed to a TKI at progression [13].

The EVAN trial is a phase 2 randomized trial on a smaller cohort of 102 patients with fully-resected stage IIIA EGFR-mutant NSCLC [21]. Patients were randomized between adjuvant chemotherapy for four cycles and erlotinib for up to two years. The primary endpoint was two-year DFS, while OS was a secondary endpoint. At a median follow-up of 33 months, the two-year DFS was 81.4% in the erlotinib group and 44.6% in the chemotherapy arm (RR 1.823, 95% CI 1.194–2.784, \( p = 0.0054 \)). While these results are promising, the sample size was small, and OS data are not yet available.
Table 1. Phase II/III studies with EGFR tyrosine kinase inhibitors (TKIs) in the adjuvant setting.

| Study      | Phase | Population                              | n   | Arm(s)                  | Patients Receiving Adjuvant Chemotherapy (%) | Median DFS (mos) | 2-Year DFS | 3-Year DFS | Median OS (mos) |
|------------|-------|-----------------------------------------|-----|-------------------------|---------------------------------------------|------------------|------------|------------|----------------|
| RADIANT [9]| III   | IB-IIIA NSCLCs, EGFR-positive by IHC and/or FISH | 623 | Erlotinib for 2 years vs. placebo | 50.6% vs. 57.1%                           | 50.5 vs. 48.2    | 75% vs. 54% | N.R.       | Not reached vs. Not reached (HR 0.90) |
| BR19 [10] | III   | IB-IIIA NSCLCs                          | 251 | Gefitinib for 2 years vs. placebo | 17% vs. 17%                               | 4.2 years vs. Not reached (HR 1.22) | N.R.       | N.R.       | 5.1 years vs. Not reached (HR 1.24) |
| SELECT [11]| II    | IA-III EGFR-mutated NSCLC               | 100 | Erlotinib for 2 years     | N.R.                                       | Not reached      | 88%        | N.R.       | Not reached            |
| CTONG1104 ADJUVANT [12]| III | II-III EGFR-mutated NSCLC               | 111 | Gefitinib for 2 years vs. vinorelbine/cisplatin | 0% vs. 100%                             | 30.8 vs. 19.8    | 39.6% vs. 32.5% | N.R.       | 75.5 vs. 62.8 (HR 0.92)  |
| EVAN [20]  | II    | IIIA EGFR-mutated NSCLC                 | 51  | Erlotinib for 2 years vs. vinorelbine/cisplatin | 0% vs. 100%                             | 42.4 vs. 21.0    | 81.4% vs. 44.6% | 54.2% vs. 19.8% | Not reached vs. Not reached (HR 0.165) |
| ADAURA [21]| III   | IB-IIIA EGFR-mutated NSCLC              | 339 | Osimertinib for 3 years vs. placebo | Not reached                               | 90% vs. 80%      | 80% vs. 28%  | Not reached            | 40% vs. Not reached (HR 0.40) |

* Intention-to-treat (ITT) population (stage II-IIIA NSCLC). Abbreviations: IHC, immunohistochemistry; FISH, fluorescent in situ hybridization; DFS, disease-free survival; OS, overall survival; mos, months; HR, hazard ratio; N.R., not reported.
Recently, the ADAURA trial was presented at the ASCO 2020 Meeting [22]. It evaluated the impact of adjuvant osimertinib, a third-generation EGFR TKI, compared to placebo in fully-resected stage IB to IIA (TNM 7) EGFR-mutant NSCLC. Patients in both arms were eligible for chemotherapy, but the trial was not stratified based on whether it was administered. The experimental arm received osimertinib until progression or up to three years. The primary endpoint was once again DFS, among the stage II to IIA patients, while DFS in the intention-to-treat population and OS were among the secondary endpoints. The results presented at the ASCO Meeting were from an off-protocol interim safety analysis after the data safety monitoring board asked to unblind the trial due to a very strong signal favoring the osimertinib arm. At this preliminary analysis, with a median follow-up of 22 months, the DFS for stage II to IIA patients was not reached in the osimertinib arm and 20.4 months in the placebo arm, with an HR of 0.17 (95% CI 0.12–0.23, \( p < 0.0001 \)). While the HR of DFS is certainly impressive, there is much controversy about whether these immature data should lead to a change in practice, as the real question is whether patients will live longer if treated earlier. Furthermore, at the ASCO 2020, the final analysis of the CTONG1104/ADJUVANT trial was presented, showing that treating EGFR positive patients with EGFR TKI delayed the relapse but did not translate into OS benefit [12]. Moreover, the ADAURA trial doesn’t address the question about the importance and need for adjuvant chemotherapy in these patients, as the majority of them received it before being randomized in the trial.

Probably the largest effort to address the role of EGFR TKI in the adjuvant setting is the ALCHEMIST trial (NCT02194738). Patients with stage IB to IIA after radical surgery will get molecular analysis, and patients whose tumor harbors an EGFR mutation will enter the EGFR mutation substudy. It is aiming to recruit 410 patients and will randomly assign patients to erlotinib for two years versus placebo. The primary endpoint is OS.

Neoadjuvant therapy has the potential to facilitate surgery by shrinking the tumor. A phase II single-arm study assessing the impact of 28 days of neoadjuvant gefitinib in stage I NSCLC found a 50% response rate among patients whose tumors harbored EGFR mutations. There was no safety signal for increased risk of surgery. Upon histologic analysis, there was more fibrotic scar tissue, lower cell proliferation, and residual tumor cells were concentrated in fibrous stroma with lymphocytic infiltration [23,24]. Three small phase II trials evaluated neoadjuvant erlotinib among patients with stage IIIA EGFR-mutant NSCLC. In spite of a response rate of 58%, the first failed to show a survival benefit compared to non-EGFR-mutated patients receiving chemotherapy [25]. The second was a single-arm trial and reported a 42% response rate, with 21% downstaging to T0-3 N0 M0. On a pathological level, 50% of patients had a partial response, while 50% had stable disease [26]. The third study compared neoadjuvant erlotinib among 15 patients whose tumors had EGFR mutations to chemotherapy in 16 patients without these alterations [27]. The authors report a trend towards better response rate, pathological response rates, and overall survival. Given the small number and heterogeneous prognosis inherent in oncogenic driven NSCLC, no conclusions can be drawn. One potential pitfall is disease flare after TKI interruption, and this will need to be evaluated in larger prospective trials [28]. The ongoing phase II EMERGING trial is comparing neoadjuvant erlotinib to cisplatin-gemcitabine in patients with stage IIIA EGFR-mutant NSCLC (NCT01407822). A neoadjuvant phase III trial of gefitinib versus carboplatin and vinorelbine among patients with stage II-IIIA EGFR-mutant NSCLC is planned (NCT03203590).

After the impressive early results of the adjuvant ADAURA trial, the neoADAURA (NCT04351555) trial will follow. It is a phase III trial that will compare neoadjuvant osimertinib, with or without chemotherapy, to chemotherapy alone in resectable NSCLC patients. The primary endpoint will be major pathological response rates, while OS and DFS will be among secondary endpoints. A phase II trial is ongoing (NCT03433469).

3. Anaplastic Lymphoma Kinase (ALK) Gene Fusions

ALK rearrangements are detected in 2 to 7% of NSCLC patients. Interestingly, this comprises under 5% of resected NSCLCs but up to 19% of stage IV cancers. This could possibly be due to the
biology of ALK driven tumors, with rapid proliferation and spread. It is interesting to note that this contrasts with EGFR mutations, which are not stage dependent [29–31].

Given the infrequency of ALK translocations in localized NSCLC, it is no surprise that there are fewer clinical trials assessing ALK inhibitors in this setting. Nonetheless, two adjuvant phase III trials are ongoing. The aforementioned ALCHEMIST trial (NCT02194738) has an arm randomizing patients with stage IB to IIIA (TNM7) fully-resected ALK-driven NSCLC to observation versus crizotinib for up to 24 months after completing standard therapy, including chemotherapy and radiotherapy, where indicated. The primary endpoint is OS, and DFS is among secondary endpoints. The second, more recent, phase III multicenter randomized adjuvant trial, ALINA (NCT03456076), is comparing alectinib to standard of care in stage IB-IIIA (TNM 7) fully resected ALK-rearranged NSCLC. This trial excludes patients with N2 stage IIIA cancer who could be candidates for postoperative radiotherapy in some centers, as this could represent a confounding factor in a high-risk group. Alectinib is administered for up to 24 months, while the control arm receives four cycles of platinum-based chemotherapy. The primary endpoint is DFS, while OS is among secondary endpoints.

Finally, a multicenter phase II trial will soon begin recruiting patients with stage IB to IIIB resectable NSCLC with a variety of oncogenic drivers, assessing the efficacy of eight weeks of neoadjuvant therapy followed by the possibility of adjuvant treatment with the same drug (NCT04302025). One arm will assess alectinib in this setting. The NCT03088930 trial is evaluating neoadjuvant crizotinib in a similar design.

4. Others Oncogenic Drivers

EGFR and ALK are two of the multitude of currently identified and targetable oncogenic drivers in NSCLC. As a reminder, in lung adenocarcinoma, targetable alterations comprise roughly half of all diseases, and the list of actionable therapeutic targets is constantly growing [32].

Front-line therapy for metastatic disease has largely shifted or is gradually moving towards a TKI approach among patients whose tumors harbor these alterations. To name a few, BRAF V600E mutations are successfully targeted by combined BRAF/MEK inhibitors, mainly dabrafenib and trametinib, with high response rates and relatively low toxicity [33]. Similarly, ROS1 rearrangements can be targeted with drugs, including crizotinib, ceritinib, lorlatinib, entrectinib, or repotrectinib [26]. MET alterations, including exon 14 mutations and amplifications, can be treated with a variety of TKIs, among the most common, crizotinib, capmatinib, and tepotinib [34–37]. NTRK fusions are a recent addition to this list, with impressive responses to entrectinib and larotrectinib [38,39]. RET fusion-positive NSCLC also appears to benefit from treatment with selpercatinib or praseltinib [40,41] The very common KRAS G12C mutation, hitherto considered undruggable, is now being targeted by small molecules, with the potential to dramatically alter the therapeutic landscape [42]. HER2 targeting appears to be moving forward in strides, with the antibody-drug conjugate, trastuzumab–deruxtecan, yielding impressive preliminary results [43]. It is important to be aware of the efficacy of these drugs, even if only in early phase trials for some, to understand the rationale for testing them in the adjuvant or neoadjuvant setting.

The abovementioned ALK trial (NCT04302025) also includes arms for ROS1 and NTRK, each to be treated by entrectinib following the same treatment pattern as the ALK arm, as well as BRAF V600E mutations to be treated by vemurafenib and cobimetinib. The primary endpoint is major pathological response, defined as 10% or lower of viable tumor cells, while OS and DFS are among secondary objectives.

A small phase II trial is ongoing, assessing the efficacy of six weeks of neoadjuvant crizotinib in patients with MET, ROS1, or ALK alterations and resectable stage IA-IIIA NSCLC (NCT03088930). Objective response rate is the primary endpoint while OS and DFS are among secondary endpoints.

These trials are summarized in Table 2. To our knowledge, no other phase II to III trials are ongoing in this setting.
Table 2. Ongoing phase II–III neoadjuvant and adjuvant trials with tyrosine kinase inhibitors (TKIs).

| Trial         | Phase Design       | Population                          | Arm(s)                          | Primary Outcome | Clinical Trial Identification |
|---------------|--------------------|-------------------------------------|---------------------------------|-----------------|------------------------------|
| ALCHEMIST     | III adjuvant       | IB-IIIA NSCLCs, EGFR-mutated NSCLC  | erlotinib for 2 years vs. placebo | OS              | NCT02194738                  |
| ALCHEMIST     | III adjuvant       | IB-IIIA NSCLCs, ALK-rearranged NSCLC| crizotinib for 2 years vs. placebo | OS              | NCT02194738                  |
| ALINA         | III adjuvant       | IB-IIIA NSCLCs, ALK-rearranged NSCLC| alectinib for 2 years vs. chemotherapy | DFS            | NCT03456076                  |
| EMERGING      | II Neoadjuvant + adjuvant | IIIA EGFR-mutated NSCLCs | erlotinib for 6 weeks then 1 year post-op vs. cisplatin-gemcitabine | ORR            | NCT01407822                  |
| NCT03203590   | III neoadjuvant    | II-IIIA EGFR-mutated NSCLC          | gefinitib for 8 weeks vs. carboplatin-vinorelbine | 2 year DFS     | NCT03203590                  |
| NeoADAURA     | III neoadjuvant    | II-IIIA EGFR-mutated NSCLC          | osimertinib +/- platinum-pemetrexed vs. platinum-pemetrexed | MPR            | NCT04351555                  |
| NCT04302025   | II Neoadjuvant +/- adjuvant | IB-IIIB NSCLC with altered ALK, ROS1, NTRK or BRAF | 8 weeks neoadjuvant +/- adjuvant with alectinib, entrectinib or vemurafenib+cobimetinib | MPR            | NCT04302025                  |
| NCT03088930   | II neoadjuvant     | IA-IIIA NSCLC with altered MET, ROS1 or ALK | crizotinib for 6 weeks | ORR            | NCT03088930                  |

Abbreviations: DFS, disease-free survival; OS, overall survival; MPR, major pathological response; ORR, objective response rate.
5. Limitations of TKIs in the Early Stage Setting

To date, no data have proven that TKIs can be curative in NSCLC, and patients’ compliance with TKI treatment could be lowered by the persistency of chronic adverse events due to long term use of TKIs in patients who are free from cancer [36,37]. In the metastatic setting, all TKIs eventually fail, through on- or off-target escape mechanisms. Similarly, treatment discontinuation can lead to a flare in tumor growth. The aim of TKI therapy in early-stage disease could comprise various options. Of course, the primordial question is whether treating microscopic residual disease could eliminate cells rather than simply suppress growth, thus increasing cure rates rather than just relapse-free survival. Only the overall survival of properly conducted trials will provide this answer. However, other goals could exist. In the neoadjuvant setting, for instance, the higher response rate of TKIs compared to chemotherapy could facilitate surgical management.

Under selective therapy-induced pressure, oncogenic-driven tumors can develop different resistant clones. While cell subpopulations develop a quiescent or dormant state of cell-cycle arrest when exposed to TKIs, some will acquire resistance alterations, whether through mutations or epigenetic changes [44].

The drug-tolerant cells are a reservoir for potential tumor growth and will lead to progression if they escape immune surveillance and proliferate. Unless we manage to reactivate quiescent cells selectively to target them, it is unlikely TKIs will be curative given this behavior [45].

Combinatory therapy targeting and inhibiting signal transduction and activator of transcription 3 (STAT3) and Src may potentially be more effective by reducing the level of lung cancer stem cells subpopulation.

6. Future Directions and Challenges

As we await the results of ongoing and planned trials of TKIs in the localized NSCLC setting, the question of which patients to treat in the non-metastatic setting may emerge. Circulating tumor DNA (ctDNA) can detect minimal residual disease among patients with operated early-stage NSCLC [46]. Similarly, ctDNA has been used to identify acquired-resistance mechanisms to TKIs [41,42,47,48]. Such an approach could have potential implications for initiating therapy upon early disease detection rather than broadly among all operated patients. It could also be a tool to monitor patients on adjuvant therapy in order to detect early resistance or relapse. These questions and more will have to be revisited in light of results of neo(adjuvant) trials. Only time will provide answers about the best care for our patients.

At the ASCO 2020 Meeting, the ADAURA presentation may have provided a glimpse of the future for adjuvant treatment in oncogenic driven mutated NSCLC. The assumption that a TKI, proven to be very effective in the metastatic setting, could and will be even more effective in early stages has become prevalent among many oncologists. There may be significant implications if the follow-up data of the ADAURA trial and the readouts from the ALINA are very positive, albeit for surrogate endpoints for OS. Oncologists may be very tempted to emulate this early-stage TKI approach in less frequent mutations, such as NTRK or RET, arguing that large trials are not feasible given the rarity of these alterations. This will generate a debate on the appropriateness and validity of extrapolating results without a formal trial; however, it is undeniable that the oncology world has already, as a consequence of preliminary results, shifted toward wider molecular genomic sequencing in early-stage NSCLC.

Funding: This research received no external funding

Conflicts of Interest: A.F. reports receiving personal fees from Bristol-Myers Squibb, Roche Holdings AG, Pfizer, Astellas, and Merck Sharp & Dohme, outside of the present work. A.A. reports receiving personal fees from Bristol-Myers Squibb, AstraZeneca, Roche Holdings AG, Pfizer, Merck Sharp & Dohme, and Boehringer Ingelheim, outside of the present work. A.R. No conflict of interest. V.G. No conflict of interest. D.C. No conflict of interest. C.R. reports roles in speaker bureaus for MSD and AstraZeneca; advisory board roles with ARCHER, Inivata, and Merck Serono; consultant roles with Mylan and Oncompass; a supported research grant from the Lung Cancer Research Foundation/Pfizer; and research support from Guardant Health and Biomark.
References

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9–29. [CrossRef]
2. Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature 2018, 553, 446–454. [CrossRef]
3. Molina, J.R.; Yang, P.; Cassivi, S.D.; Schild, S.E.; Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, and survival. Mayo Clin. Proc. 2008, 83, 584–594. [CrossRef]
4. Gloeckler Ries, L.A.; Reichman, M.E.; Lewis, D.R.; Hankey, B.F.; Edwards, B.K. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8, 541–552. [CrossRef]
5. Pisters, K.M.W.; Chevalier, T.L. Adjuvant Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2005, 23, 3270–3278. [CrossRef] [PubMed]
6. Group, N.M.-a.C.; Arriagada, R.; Auperin, A.; Burdett, S.; Higgins, J.P.; Johnson, D.H.; Le Chevalier, T.; Le Pechoux, C.; Parmar, M.K.B.; Pignon, J.P.; et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet 2010, 375, 1267–1277. [CrossRef]
7. Pignon, J.P.; Tribodet, H.; Scagliotti, G.V.; Douillard, J.Y.; Shepherd, F.A.; Stephens, R.J.; Dunant, A.; Torri, V.; Rosell, R.; Seymour, L.; et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008, 26, 3552–3559. [CrossRef] [PubMed]
8. Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data. Lancet 2014, 383, 1561–1571. [CrossRef]
9. Kelly, K.; Altorki, N.K.; Eberhardt, W.E.; O’Brien, M.E.; Spigel, D.R.; Crino, L.; Kim, J.H.; Cho, E.K.; Hoffman, P.C.; et al. Adjuvant Erlotinib Versus Placebo in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J. Clin. Oncol. 2015, 33, 4007–4014. [CrossRef]
10. Goss, G.D.; O’Callaghan, C.; Lorimer, I.; Tsao, M.-S.; Masters, G.A.; Jett, J.; Edelman, M.J.; Lilienbaum, R.; Choy, H.; Khuri, F.; et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J. Clin. Oncol. 2013, 31, 3320–3326. [CrossRef]
11. Pennell, N.A.; Neal, J.W.; Chaft, J.E.; Azzoli, C.G.; Jänne, P.A.; Govindan, R.; Evans, T.L.; Costa, D.B.; Wakelee, H.A.; Heist, R.S.; et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2019, 37, 97–104. [CrossRef] [PubMed]
12. Wu, Y.-L.; Zhong, W.; Wang, Q.; Mao, W.; Xu, S.-T.; Wu, L.; Chen, C.; Cheng, Y.; Xu, L.; Wang, J. CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. J. Clin. Oncol. 2020, 38, 9005. [CrossRef]
13. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139. [CrossRef]
14. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497–1500. [CrossRef] [PubMed]
15. Ramalingam, S.; Gray, J.; Ohe, Y.; Cho, B.; Vansteenkiste, J.; Zhou, C.; Reungwetwattana, T.; Cheng, Y.; Chewaskulyong, B.; Shah, R. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. Ann. Oncol. 2019, 30, v914–v915. [CrossRef]
16. Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sruanponpong, V.; Chao, T.-Y.; Nakagawa, K.; Chu, D.-T.; Saijo, N. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 2011, 29, 2866–2874. [CrossRef]
17. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open label, randomised phase 3 trial. *Lancet Oncol.* 2012, 13, 239–246. [CrossRef]

18. Yang, J.C.-H.; Schuler, M.H.; Yamamoto, N.; O’Byrne, K.J.; Hirsh, V.; Mok, T.; Geater, S.L.; Orlov, S.V.; Tsai, C.-M.; Boyer, M.J.; et al. LUX-Lung 3: A randomised, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J. Clin Oncol.* 2012, 30, LBA7500-LBA7500. [CrossRef]

19. Wu, Y.-L.; Zhou, C.; Hu, C.-P.; Feng, J.; Lu, S.; Huang, Y.; Li, W.; Hou, M.; Shi, J.H.; Lee, K.Y. Afatinib versus cisplatin plus gemcitabine as first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. *Lancet Oncol.* 2014, 15, 213–222. [CrossRef]

20. Chevallier, M.; Tsantoulis, P.; Addeo, A.; Friedlaender, A. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer. *Cancer Genom Proteom.* 2020, 17, 597–603. [CrossRef]

21. Yue, D.; Xu, S.; Wang, Q.; Li, X.; Shen, Y.; Zhao, H.; Chen, C.; Mao, W.; Liu, W.; Liu, J.; et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): A randomised, open-label, phase 2 trial. *Lancet Respir. Med.* 2018, 6, 863–873. [CrossRef]

22. Herbst, R.S.; Tsuiboi, M.; John, T.; Grobé, C.; Majem, M.; Goldman, J.W.; Kim, S.W.; Marmol, D.; Rukazenkov, Y.; Wu, Y.-L. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. *J. Clin. Oncol.* 2020, 38. [CrossRef]

23. Lara-Guerra, H.; Waddell, T.K.; Salvarrey, M.A.; Joshua, A.M.; Chung, C.T.; Paul, N.; Boerner, S.; Sakurada, A.; Ludkovski, O.; Ma, C.; et al. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. *J. Clin. Oncol.* 2009, 27, 6229–6236. [CrossRef] [PubMed]

24. Lara-Guerra, H.; Chung, C.T.; Schwock, J.; Pintlile, M.; Hwang, D.M.; Leighl, N.B.; Waddell, T.K.; Tsao, M.S. Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. *Lung Cancer* 2012, 76, 235–241. [CrossRef] [PubMed]

25. Zhong, W.; Yang, X.; Yan, H.; Zhang, X.; Su, J.; Chen, Z.; Liao, R.; Nie, Q.; Dong, S.; Zhou, Q.; et al. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. *J. Hematol. Oncol.* 2015, 8, 54. [CrossRef]

26. Xiong, L.; Li, R.; Sun, J.; Lou, Y.; Zhang, W.; Bai, H.; Wang, H.; Shen, J.; Jing, B.; Shi, C.; et al. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. *Oncologist* 2019, 24, e157–e164. [CrossRef]

27. Xiong, L.; Lou, Y.; Bai, H.; Li, R.; Xia, J.; Fang, W.; Zhang, J.; Han-Zhang, H.; Lizaso, A.; Li, B.; et al. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. *J. Int. Med. Res.* 2019. [CrossRef]

28. Chaft, J.E.; Oxnard, G.R.; Sima, C.S.; Kris, M.G.; Miller, V.A.; Riely, G.J. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. *Clin. Cancer Res.* 2011, 17, 6298–6303. [CrossRef] [PubMed]

29. Addeo, A.; Tabbò, F.; Robinson, T.; Buffoni, L.; Novello, S. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario. *Crit. Rev. Oncol. Hematol.* 2018, 122, 150–156. [CrossRef]

30. Friedlaender, A.; Banna, G.; Patel, S.; Addeo, A. Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. *Curr. Treat. Opt. Oncol.* 2019, 20, 79. [CrossRef]

31. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007, 448, 561–566. [CrossRef] [PubMed]

32. Massó-Vallés, D.; Beaulieu, M.-E.; Soucek, L. MYC, MYCL, and MYCN as therapeutic targets in lung cancer. *Expert Opin. Ther. Targets* 2020, 24, 101–114. [CrossRef] [PubMed]

33. Frisone, D.; Friedlaender, A.; Malapelle, U.; Banna, G.; Addeo, A. A BRAF new world. *Crit. Rev. Oncol. Hematol.* 2020, 152, 103008. [CrossRef] [PubMed]
34. Shaw, A.T.; Solomon, B.J.; Chiari, R.; Riely, G.J.; Besse, B.; Soo, R.A.; Kao, S.; Lin, C.-C.; Bauer, T.M.; Clancy, J.S.; et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: A multicentre, open-label, single-arm, phase 1–2 trial. *Lancet Oncol.* 2019, 20, 1691–1701. [CrossRef]

35. Groen, H.J.; Akerley, W.L.; Souquet, P.J.; Laack, E.; Han, J.-Y.; Smit, E.F.; Mansfield, A.S.; Garon, E.B.; Wolf, J.; Tan, D.S.W. Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): Results from cohort 6 of the phase 2 GEOMETRY mono-1 study. *J. Clin. Oncol.* 2020, 38. [CrossRef]

36. Paik, P.K.; Felip, E.; Veillon, R.; Sakai, H.; Cortot, A.B.; Garassino, M.C.; Mazieres, J.; Viteri, S.; Senellart, H.; Van Meerbeeck, J.; et al. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. *N. Engl. J. Med.* 2020. [CrossRef]

37. Friedlaender, A.; Drilon, A.; Banna, G.L.; Peters, S.; Addeo, A. The METeoric rise of MET in lung cancer. *Cancer* 2020.

38. Hong, D.S.; DuBois, S.G.; Kummar, S.; Farago, A.F.; Albert, C.M.; Rohrberg, K.S.; van Tilburg, C.M.; Nagasubramanian, R.; Berlin, J.D.; Federman, N. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol.* 2020, 21, 531–540. [CrossRef]

39. Doeele, R.C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A.T.; Farago, A.F.; Blakely, C.M.; Seto, T.; Cho, B.C.; Tosi, D. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1–2 trials. *Lancet Oncol.* 2020, 21, 271–282. [CrossRef]

40. Drilon, A.; Oxnard, G.R.; Tan, D.S.W.; Loong, H.H.F.; Johnson, M.; Gainor, J.; McCoach, C.E.; Gautschi, O.; Besse, B.; Cho, B.C.; et al. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* 2020, 383, 813–824. [CrossRef]

41. Lee, D.H.; Subbiah, V.; Gainor, J.F.; Taylor, M.H.; Zhu, V.W.; Doeele, R.C.; Lopes, G.; Baik, C.; Garralda, E.; Gadgeel, S.M.; et al. Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). *Ann. Oncol.* 2019, 30, ix122. [CrossRef]

42. Friedlaender, A.; Drilon, A.; Weiss, G.J.; Banna, G.L.; Peters, S.; Addeo, A. KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. *Cancer Treat. Rev.* 2020, 85, 101978. [CrossRef] [PubMed]

43. Smit, E.F.; Nakagawa, K.; Nagasaka, M.; Felip, E.; Goto, Y.; Li, B.T.; Pacheco, J.M.; Murakami, H.; Barlesi, F.; Saltos, A.N.; et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. *J. Clin. Oncol.* 2020, 38, 9504-9504. [CrossRef]

44. Vallette, F.M.; Olivier, C.; Lézot, F.; Oliver, L.; Cochoenneau, D.; Lalier, L.; Cartron, P.F.; Heymann, D. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. *Biochem. Pharmacol.* 2019, 162, 169–176. [CrossRef]

45. Recasens, A.; Munoz, L. Targeting Cancer Cell Dormancy. *Trends Pharmacol. Sci.* 2019, 40, 128–141. [CrossRef]

46. Chaudhuri, A.A.; Chabon, J.J.; Lovejoy, A.F.; Newman, A.M.; Stehr, H.; Azad, T.D.; Khodadoust, M.S.; Esfahani, M.S.; Liu, C.L.; Zhou, L.; et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. *Cancer Discov.* 2017, 7, 1394–1403. [CrossRef]

47. Dagogo-Jack, I.; Brannon, A.R.; Ferris, L.A.; Campbell, C.D.; Lin, J.J.; Schultz, K.R.; Ackil, J.; Stevens, S.; Dardaei, L.; Yoda, S.; et al. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. *JCO Precis Oncol.* 2018. [CrossRef]

48. Chabon, J.J.; Simmons, A.D.; Lovejoy, A.F.; Esfahani, M.S.; Newman, A.M.; Haringsma, H.J.; Kurtz, D.M.; Stehr, H.; Scherer, F.; Karlovich, C.A.; et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat. Commun.* 2016, 7, 11815. [CrossRef]